Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today…
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…